Tags

Type your tag names separated by a space and hit enter

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
J Am Acad Dermatol. 1999 Oct; 41(4):550-4.JA

Abstract

BACKGROUND

Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase. Finasteride is a type 2 5alpha-reductase inhibitor that has been shown to slow further hair loss and improve hair growth in men with androgenetic alopecia.

OBJECTIVE

We attempted to determine the effect of finasteride on scalp skin and serum androgens.

METHODS

Men with androgenetic alopecia (N = 249) underwent scalp biopsies before and after receiving 0.01, 0.05, 0.2, 1, or 5 mg daily of finasteride or placebo for 42 days.

RESULTS

Scalp skin DHT levels declined significantly by 13.0% with placebo and by 14.9%, 61.6%, 56. 5%, 64.1%, and 69.4% with 0.01, 0.05, 0.2, 1, and 5 mg doses of finasteride, respectively. Serum DHT levels declined significantly (P <.001) by 49.5%, 68.6%, 71.4%, and 72.2% in the 0.05, 0.2, 1, and 5 mg finasteride treatment groups, respectively.

CONCLUSION

In this study, doses of finasteride as low as 0.2 mg per day maximally decreased both scalp skin and serum DHT levels. These data support the rationale used to conduct clinical trials in men with male pattern hair loss at doses of finasteride between 0.2 and 5 mg.

Authors+Show Affiliations

Drake L
University of Oklahoma Health Sciences, Oklahoma City, USA.
Hordinsky M
No affiliation info available
Fiedler V
No affiliation info available
Swinehart J
No affiliation info available
Unger WP
No affiliation info available
Cotterill PC
No affiliation info available
Thiboutot DM
No affiliation info available
Lowe N
No affiliation info available
Jacobson C
No affiliation info available
Whiting D
No affiliation info available
Stieglitz S
No affiliation info available
Kraus SJ
No affiliation info available
Griffin EI
No affiliation info available
Weiss D
No affiliation info available
Carrington P
No affiliation info available
Gencheff C
No affiliation info available
Cole GW
No affiliation info available
Pariser DM
No affiliation info available
Epstein ES
No affiliation info available
Tanaka W
No affiliation info available
Dallob A
No affiliation info available
Vandormael K
No affiliation info available
Geissler L
No affiliation info available
Waldstreicher J
No affiliation info available

MeSH

5-alpha Reductase InhibitorsAdolescentAdultAlopeciaAndrogensAndrostane-3,17-diolDihydrotestosteroneDouble-Blind MethodEnzyme InhibitorsFinasterideHumansMaleMiddle AgedScalpTestosterone

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10495374

Citation

Drake, L, et al. "The Effects of Finasteride On Scalp Skin and Serum Androgen Levels in Men With Androgenetic Alopecia." Journal of the American Academy of Dermatology, vol. 41, no. 4, 1999, pp. 550-4.
Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550-4.
Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S. J., Griffin, E. I., Weiss, D., Carrington, P., Gencheff, C., Cole, G. W., Pariser, D. M., Epstein, E. S., ... Waldstreicher, J. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology, 41(4), 550-4.
Drake L, et al. The Effects of Finasteride On Scalp Skin and Serum Androgen Levels in Men With Androgenetic Alopecia. J Am Acad Dermatol. 1999;41(4):550-4. PubMed PMID: 10495374.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. AU - Drake,L, AU - Hordinsky,M, AU - Fiedler,V, AU - Swinehart,J, AU - Unger,W P, AU - Cotterill,P C, AU - Thiboutot,D M, AU - Lowe,N, AU - Jacobson,C, AU - Whiting,D, AU - Stieglitz,S, AU - Kraus,S J, AU - Griffin,E I, AU - Weiss,D, AU - Carrington,P, AU - Gencheff,C, AU - Cole,G W, AU - Pariser,D M, AU - Epstein,E S, AU - Tanaka,W, AU - Dallob,A, AU - Vandormael,K, AU - Geissler,L, AU - Waldstreicher,J, PY - 1999/9/25/pubmed PY - 1999/9/25/medline PY - 1999/9/25/entrez SP - 550 EP - 4 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 41 IS - 4 N2 - BACKGROUND: Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase. Finasteride is a type 2 5alpha-reductase inhibitor that has been shown to slow further hair loss and improve hair growth in men with androgenetic alopecia. OBJECTIVE: We attempted to determine the effect of finasteride on scalp skin and serum androgens. METHODS: Men with androgenetic alopecia (N = 249) underwent scalp biopsies before and after receiving 0.01, 0.05, 0.2, 1, or 5 mg daily of finasteride or placebo for 42 days. RESULTS: Scalp skin DHT levels declined significantly by 13.0% with placebo and by 14.9%, 61.6%, 56. 5%, 64.1%, and 69.4% with 0.01, 0.05, 0.2, 1, and 5 mg doses of finasteride, respectively. Serum DHT levels declined significantly (P <.001) by 49.5%, 68.6%, 71.4%, and 72.2% in the 0.05, 0.2, 1, and 5 mg finasteride treatment groups, respectively. CONCLUSION: In this study, doses of finasteride as low as 0.2 mg per day maximally decreased both scalp skin and serum DHT levels. These data support the rationale used to conduct clinical trials in men with male pattern hair loss at doses of finasteride between 0.2 and 5 mg. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/10495374/The_effects_of_finasteride_on_scalp_skin_and_serum_androgen_levels_in_men_with_androgenetic_alopecia_ DB - PRIME DP - Unbound Medicine ER -